Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial.

SK, Sharma; K, Katoch; R, Sarin; R, Balambal; Jain N, Kumar; N, Patel; KJR, Murthy; N, Singla; PK, Saha; A, Khanna; U, Singh; S, Kumar; A, Sengupta; JN, Banavaliker; DS, Chauhan; S, Sachan; M, Wasim; S, Tripathi; N, Dutt; N, Jain; N, Joshi; SRR, Penmesta; S, Gaddam; S, Gupta; B, Khamar; B, Dey; DK, Mitra; SK, Arora; S, Bhaskar; R, Rani

doi:10.1038/s41598-017-03514-1

Public

Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trial.

Shared by NobleBlocks on Jun 13, 2017 • 12:00 AM UTC

Authors:

Sharma SK

Katoch K

Sarin R

Abstract

Prolonged treatment of tuberculosis (TB) often leads to poor compliance, default and relapse, converting primary TB patients into category II TB (Cat IITB) cases, many of whom may convert to multi-drug resistant TB (MDR-TB). We have evaluated the immunotherapeutic potential of Mycobacterium indicus ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!